SlowBull
The market, slowly. THURSDAY, 24 SEPTEMBER 2026
← All news
Markets

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

1 source ·1 article ·Sep 2, 16:32 UTC Avis Budget Novartis

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·Sep 2, 16:32 UTC

Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts

Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.